Haematology - Acute Leukaemia & MDS

A LIST OF OUR EARLY PHASE haematology (Acute Leukaemia & MDS) TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

74856665AML1001 A Phase 1, First in Human (FIH), Dose Escalation Study of JNJ-74856665 (dihydroorotate dehydrogenase [DHODH] Inhibitor) in Participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Local Project Reference:	135994
Principal Investigator:	Dr. Jenny O'Nions
Drug Class/ Treatrment:	Dihydroorotate Dehydrogenase (DHODH) Inhibitor: JNJ-74856665 Arm A: Monotherapy Arm B: Combination with Azacitidine (AZA)
Patient Population:	Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

CCS1477-02 An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies
Local Project Reference:	121140
Principal Investigator:	Dr. Jenny O'Nions
Drug Class/ Treatrment:	P300/CBP Inhibitor: CCS1477 Monotherapy
Patient Population:	Advanced Haematological Malignancies
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

EP0042-101 A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate theSafety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies.
Local Project Reference:	134892
Principal Investigator:	Dr. Jenny O'Nions
Drug Class/ Treatrment:	FLT3 inhibitor & Aurora Kinase Inhibitor: EP0042 Oral administration
Patient Population:	Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS)
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

CL1-65487-003 Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multicentre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment
Local Project Reference:	136715
Principal Investigator:	Dr. Jenny O'Nions
Drug Class/ Treatrment:	BCL2 Inhibitor: S65487 Combination S65487 and Azacitidine. Receiving 7 days Azacitidne and weekly S65487 infusions through the vein every 28 days.
Patient Population:	Acute Myeloid Leukaemia
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

PROMISE Investigation into the combination of PLX2853 with Ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone.
Local Project Reference:	136172
Principal Investigator:	Dr. Jenny O'Nion
Drug Class/ Treatrment:	PLX2853 (BET Inhibitor) + Ruxolitinib (JAK Inhibitor)
Patient Population:	Intermediate or High-Risk Myelofibrosis
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

CPI-0610 / MANIFEST CPI-0610 With or Without Ruxolitinib - A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
Local Project Reference:	18/0336
Principal Investigator:	Dr. Mallika Sekhar
Drug Class/ Treatrment:	CPI-0610 - BET Inhibitor Monotherapy or with Ruxolitinib - JAK1 and JAK2 Inhibitor
Patient Population:	Phase 2 - Myelofibrosis
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

SeluDex SeluDex: International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia
Local Project Reference:	18/0068
Principal Investigator:	Prof. Adele Fielding
Drug Class/ Treatrment:	Selumetinib (MEK Inhibitor) + Dexamethasone
Patient Population:	Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

AUTO-1 AUTO1 in relapsed or refractory B-ALL : AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
Local Project Reference:	127550
Principal Investigator:	Dr. Claire Roddie
Drug Class/ Treatrment:	AUTO1 (CAR T-Cell Therapy Targeting CD19)
Patient Population:	RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

FEDORA FEDORA : A phase II study to evaluate the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis
Local Project Reference:	146196
Principal Investigator:	Dr. Donal McLornan
Drug Class/ Treatrment:	Fedratanib (JAK2 Inhibitor) + Ropeginterferon Alfa-2b (Pegylated Interferon)
Patient Population:	Myelofibrosis
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

ELECTRA A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Local Project Reference:	145018
Principal Investigator:	Dr. Satyen Gohil
Drug Class/ Treatrment:	ELA026 (IgG1 SIRP-Directed Monoclonal Antibody)
Patient Population:	Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Adults and Adolescents (≥12 years at the time of HLH diagnosis)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

Principal Investigator(s)

Dr. jenny o'nions

Consultant Haematologist